Clinical Trials Browser

Recruiting × Carcinoma in Situ × 90 days × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT06833073 2026-04-06

INTerpath-011

Phase 2 Recruiting

308 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT02402244 2026-02-27

Project: Every Child for Younger Patients With Cancer

Recruiting

75,000 enrolled

CNSDermatologicEndocrineLymphoidMyeloidNETSarcoma

Carcinoma in Situ, Ganglioneuroma, Lymphoproliferative Disorders, Melanoma, Myeloproliferative Disorders, Neoplasms, Pheochromocytoma, Central Nervous System Neoplasms, Nephroma, Mesoblastic, Desmoid Tumors, Neuroendocrine Tumors

NCT06115486 2026-02-04

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

Phase NA Recruiting

30 enrolled

Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma in Situ, Hypertrophy, Motor Activity, Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Phase 1/2 Recruiting

350 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

INTerpath-011

Project: Every Child for Younger Patients With Cancer

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer

ADVANCED-2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin